

# Author Index Volume 52 July-December 1995

- Acosta, M., 17  
 Aire, T.A., 255, 261  
 Aitken, R.J., 241  
 Allen-Davis, J., 45  
 Amatya, R., 17  
 Anderson, F., 313  
 Anderson, F.D., 167  
 Anderson, N.G., 287  
 Anderson, R.A., 115  
 Andersson, K., 175  
 Ankum, W.M., 337  
 Arcner, D.F., 167  
 Asthana, O.P., 297, 301  
 Athayde, C., 111  
 Aydinlik, S., 343
- Bajaj, J.S., 121, 381  
 Bancroft, J., 363  
 Barbosa, I., 111  
 Bateman, L., 159  
 Bennink, H.C., 357  
 Benzi, G., 93  
 Biro, F.M., 283  
 Bossuyt, P.M.M., 337  
 Braunschweig, T., 343  
 Broome, M., 13  
 Buekens, P., 23  
 Bundren, J.C., 277  
 Burnhill, M.S., 137
- Castracane, V.D., 371  
 Chatterton, Jr, R.T., 195  
 Chen, C., 99  
 Chen, J., 63  
 Chen, Y., 129  
 Cheng, J., 63  
 Ciuffetti, G., 151  
 Clarkson, J.S., 241  
 Clayton, J., 13  
 Coata, G., 151  
 Cosmi, E.V., 151  
 Coutinho, E., 111  
 Creinin, M.D., 41  
 Crook, D., 143  
 Cui, Y., 63
- Deniaud, F., 223  
 Devenport, M., 143  
 Di Renzo, G.C., 151  
 Diczfalusy, E., 1  
 Dieben, T., 357  
 Ditmore, J.R., 159
- Du, M., 99  
 Dugoff, L., 45  
 Düsterberg, B., 229
- Ekwempu, C., 17  
 Elger, W., 187  
 Endrikat, J., 229  
 Exalto, N., 357
- Fährnich, M., 187  
 Farley, T.M.M., 363  
 Farr, G., 17  
 Ferraroni, M., 93  
 Fink, W., 215  
 Fotherby, K., 13  
 Frank, M.L., 159  
 Friel, P., 223
- Gao, Y., 99  
 Garza-Chapa, R., 377  
 Gaspard, U.J., 237  
 Gebbie, A.E., 221  
 Gerofi, J., 223  
 Gillan, L., 317  
 Gimpel, T., 371  
 Glasier, A., 221  
 Godsland, I.F., 143  
 Goldzieher, J.W., 327, 371  
 González-Garza, M.T., 377  
 González-Quiroga, G., 377  
 Graham, C.A., 363  
 Grimes, D.A., 137  
 Grubb, G.S., 287  
 Gu, S., 99  
 Gu, Z., 57, 63  
 Gudmundson, J., 35  
 Gupta, R.C., 297, 301  
 Gurr, S., 343
- Hasan, S.H., 187  
 He, X., 99  
 Hendrick, J.C., 237  
 Hillard, P.J.A., 137, 283  
 Hodgen, G.D., 313  
 Hu, J., 63  
 Huimin, F., 349  
 Hurst, B.S., 45
- Ilegbodu, A.E., 159  
 Islam, M.M., 181
- Jaques, M.-A., 229  
 Jernstrom, H., 51
- Jeyendran, R.S., 195  
 Jonasson, K., 175  
 Jones, A.R., 317  
 Jones, III, O.W., 45
- Kaufmann, J., 343  
 Kazer, R.R., 195  
 Kim, S., 313  
 Kinger, S., 121, 381  
 Kisninci, H., 17  
 Klinger, G., 343  
 Knutsson, M., 51  
 Kollar, L.M., 283  
 Kumar, P.K.S., 121, 381
- La Vecchia, C., 93  
 Ladipo, O., 111  
 Lal, J., 297, 301  
 Lian, S., 63  
 Lidegaard, Ø., 85  
 Lindstedt, G., 175  
 Liu, X., 63  
 Liu, Y., 99  
 Lombardini, R., 151  
 Lozano-Garza, G., 377  
 Luo, H., 57, 63  
 Luukkainen, T., 269
- Maglaya, C., 363  
 Mahmud, M., 181  
 Mauck, C.K., 167  
 Mayerhofer, M., 229  
 McDougall, C., 215  
 McKinney, S., 277  
 Meng, F., 99  
 Milmlow, D., 317  
 Milsom, I., 175  
 Mol, B.W.J., 337  
 Moore, D., 287  
 Moore, L.L., 215  
 Moutos, D., 105  
 Müller, U., 229
- Naessen, T., 35  
 Nervo, P., 237  
 Nityanand, S., 297, 301  
 Nwoha, P.U., 249, 255, 261
- Olsson, H., 51  
 Olsson, S.E., 35, 111
- Pal, P.C., 121, 381

- Paliwal, J.K., 301  
Parazzini, F., 93  
Park, M., 41  
Pelissier, C., 229  
Peters, A.J., 195  
Poindexter, III, A.N., 159  
Premakumara, G.A.S., 203  
Pruthi, J.S., 381
- Qi, L., 99
- Rajalakshmi, M., 121, 381  
Ramos, R., 363  
Ratnasooriya, W.D., 203, 241  
Rauh, J.L., 283  
Ray, R.M., 307  
Rosenberg, M.J., 137  
Rosenthal, S.L., 283  
Rossi, G., 93  
Rybo, G., 175
- Said-Fernández, S., 377  
Schelhorn, P., 343  
Schlaff, W.D., 45  
Sharma, D.N., 121  
Shirley, B., 277  
Shuhua, Q., 349  
Siegert, C., 343  
Singh, M.M., 187
- Sivin, I., 99  
Smith, S., 105  
Snipes, W., 313  
Sweeting, V., 221
- Teng, C.S., 129, 389  
The WHO Collaborative Study of  
Neoplasia and Steroid Con-  
traceptives, 307  
Thomas, D.B., 307  
Tillekeratne, L.M.V., 203  
Toivonen, J., 269  
Tozzi, L., 93
- Ulmsten, U., 111  
UNDP, UNFPA, and WHO Spe-  
cial Programme of Research,  
Development and Research  
Training in Human Repro-  
duction, World Bank: IUD  
Research Group, 77
- Valuck, R., 215  
van den Brûle, F.A., 237  
van der Does, J., 357  
Van der Veen, F., 337  
Ventura, F., 151  
Viniestra-Sibal, A., 167
- Wallace, E.M., 115  
Wang, D., 99  
Wang, J., 63  
Wang, P., 99  
Waugh, M.S., 137  
Wendler, J., 343  
Wentz, A.C., 195  
White, D.R., 241  
Wollast, E., 23  
Wu, F.C.W., 115  
Wu, S., 57, 63, 99  
Wynn, V., 143
- Xiong, X., 23  
Xu, L., 63  
Xu, R., 63
- Yang, N.Y., 129  
Ying, L., 99
- Zacur, H., 105  
Zamah, N.M., 327  
Zenger, E., 349  
Zhang, G., 57  
Zhang, L., 99  
Zhu, P., 57, 63  
Zhu, X., 57

# Subject Index Volume 52 July-December 1995

- Acceptability,
  - condom use, 223
  - methotrexate + misoprostol, 41
  - Norplant implants, 159
- Adolescent contraceptive use, 181
- Adolescents, Norplant implants use, 283
- Anordiol, effect on uterus and vagina (rat), 195
- Antide, gonadotropin-releasing hormone agonist, 381
- Antisteroid antibodies, OC users, 237
- Barrier contraceptive, Lea's Shield, 167
- Barrier contraceptive use, risk of ectopic pregnancy, 93
- Blood chemistry, effect of gossypol (male rat), 249
- Blood pressure, combined OCs, 143
- Blood viscosity, effect of triphasic ethinyl estradiol + gestodene, 151
- Bone density, effects of progestogen-only contraceptives, 15
- Breast milk, centchroman levels, 301
- 3-Bromopyruvate, effect on spermatozoa (boar), 317
- Buccal administration, testosterone, 313
- Centchroman, pharmacokinetics, 297
- Centchroman concentration, serum and breast milk, 301
- Cerebral thromboembolism risk, OC use, 85
- Cervical carcinomas, depo-medroxyprogesterone acetate use, 307
- Chloroquine,
  - effect on cholesterol and triglycerides levels (male rat), 261
  - effect on serum electrolytes (male rat), 255
- Cholesterol level, effect of gossypol + chloroquine (male rat), 261
- Clinical performance,
  - Lippes Loop, 17
  - TCu 380A, 17
- Clinical trial,
  - ethinylestradiol + desogestrel, 229
  - ethinylestradiol + gestodene, 229
  - FlexiGard, 77
  - Norplant implants, 45, 99, 283, 287, 349
  - TCu 380A, 77
- Clomiphene citrate, effect on uterus and vagina (rat), 195
- Coagulation parameters, triphasic ethinyl estradiol + gestodene, 151
- Combined OCs,
  - effect on blood pressure, 143
  - metabolic effects, 143
- Compliance, oral contraceptive use, 137
- Condom, design and user acceptability, 223
- Contraceptive efficacy, hormone replacement therapy, 221
- Contraceptive mechanism, Sri Lankan marine red algae (rat), 203
- Contraceptive method use, risk of ectopic pregnancy, 93, 337
- Early removal, Norplant implants, 159
- Ectopic pregnancy,
  - contraceptive methods, 337
  - effect of IUD use, 23
  - effect of past contraceptive method use, 93
- Emergency contraceptive, consensus statement, 211
- Endometrium, effect of levonorgestrel-releasing IUD, 57, 63
- Erythrocytic enzymes, effect of gossypol (male hamster), 377
- Ethinylestradiol + cyproterone acetate, 343
- Ethinylestradiol + desogestrel, 229, 357
- Ethinylestradiol + gestodene, 151, 229
- Ethinylestradiol + levonorgestrel, 13, 343, 357, 363
- Ethinylestradiol + norethindrone, 105
- FlexiGard, frameless IUD, 77
- FSH (follicle stimulating hormone)
  - FSH levels, effect of oral contraceptive use, 51
- Gossypol,
  - effect on blood chemistry (male rat), 249
  - effect on cholesterol and triglycerides levels (male rat), 261
  - effect on erythrocytic enzymes (male hamster), 377
  - effect on serum electrolytes (male rat), 255
  - effect on spermatocytes (rat), 389
  - effect on spermatogenesis (rat), 129
- Gyne-T 380S, 175
- Hormonal parameters, effect of testosterone buciclate (male monkey), 121
- Hormonal replacement therapy, 371
- Hormone levels, effect of ethinyl estradiol + norethindrone, 105
- Hormone replacement therapy, 221
- Implant contraceptive,
  - levonorgestrel, 35, 45, 99, 159, 215, 283, 287, 349
  - norgestrol acetate, 111

- Injectable contraceptive, depot-medroxyprogesterone acetate, 35, 215, 307
- Intrauterine device (IUD),  
FlexiGard, 77  
Gyne-T 380S, 175  
Lippes Loop, 17  
releasing levonorgestrel, 57, 63, 269  
TCu 380A, 17, 77
- Iron status, Gyne-T 380S, 175
- IUD (see intrauterine device)
- IUD use, risk of ectopic pregnancy, 23, 93
- Labeling guidance text, progestin-only OCs, 71
- Lea's Shield, vaginal barrier contraceptive, 167
- Levonorgestrel,  
effect on bone density, 35  
effect on ovaries, 13  
effect on well-being and sexuality, 363  
post-coital contraceptive (mouse), 277
- Levonorgestrel-releasing IUD, effect on endometrium, 57, 63, 269
- LH (luteinizing hormone)
- LH levels, effect of oral contraceptive use, 51
- Lipid metabolism, triphasic ethinyl estradiol + gestodene, 151
- Lipoproteins, effect of testosterone enanthate, 115
- Lippes Loop, 17
- Male contraceptive, intramuscular testosterone enanthate, 115
- Marine red algae, contraceptive mechanism (rat), 203
- Medical abortion, methotrexate + misoprostol, 41
- Medroxyprogesterone acetate,  
effect on bone density, 35  
effect on weight gain, 215  
risk of cervical carcinomas, 307
- Menopause, switch from OCs to hormonal replacement therapy, 371
- Menstrual blood loss, Gyne-T 380S, 175
- Metabolic effects,  
combined OCs, 143  
nomegestrol acetate, 111
- Methotrexate + misoprostol, medical abortion, 41
- Minipills, labeling guidance text, 71
- Morning-after contraception, 211
- Nomegestrol acetate subdermal implant, 111
- Nonoxynol-9, effect on sperm motility, 241
- Norethisterone, 13
- Norplant® subdermal implants, 35, 45, 99, 159, 215, 283, 287, 349
- OC use,  
cerebral thromboembolism risk, 85  
compliance, 137  
effect on FSH and LH levels, 51  
risk of ectopic pregnancy, 93  
switch to hormonal replacement therapy, 371
- OC users, vascular events, 237
- Onapristone, effect on pregnancy (guinea pig), 187
- Oral contraceptive (OC),  
centchroman, 297, 301  
combined formulations, 143  
ethinylestradiol + cyproterone acetate, 343  
ethinylestradiol + desogestrel, 229, 357  
ethinylestradiol + gestodene, 229  
ethinylestradiol + levonorgestrel, 343, 357, 363  
ethinylestradiol + norethindrone, 105  
levonorgestrel, 13, 363  
minipills, 71  
norethisterone, 13  
progestin-only, 71  
side effects, 327  
triphasic ethinylestradiol + gestodene, 151  
triphasic ethinylestradiol + levonorgestrel, 13
- Ovarian activity,  
effect of triphasic ethinylestradiol + levonorgestrel, 357  
effect of triphasic ethinylestradiol + desogestrel, 357
- Ovarian cyst formation, effect of oral contraceptives, 13
- Ovulation, effect of hormone replacement therapy, 221
- Pharmacokinetics,  
centchroman, 297  
testosterone, 313
- Phoniatric examinations, use of OCs, 343
- Post-coital contraception, 211
- Post-coital contraceptive, levonorgestrel pellets (mouse), 277
- Pregnancy, effect of Onapristone (guinea pig), 187
- Prempak-C, hormone replacement therapy, 221
- Progestin-only OCs, labeling guidance text, 71
- Progestogen-only OCs, effect on bone density, 35
- Propranolol, effect on sperm motility, 241
- Psychological effects, use of OCs, 363
- Removal, Norplant implants, 159
- Reproductive health, commentary, 1
- Reproductive parameters, effect of testosterone buccinate (male monkey), 121
- Reproductive tract infections and HIV/AIDS, 1
- Sexuality, effect of OCs, 363
- Side effects, oral contraceptives, 327
- Sperm motility, effect of nonoxynol-9 + propranolol, 241
- Spermatocytes, effect of gossypol (rat), 389
- Spermatogenesis,  
effect of Antide + testosterone buccinate (monkey), 381  
effect of gossypol (rat), 129
- Spermatozoa, effect of 3-bromopyruvate (boar), 317
- Sri Lankan marine red algae, contraceptive mechanism (rat), 203

Switch from OCs to hormonal replacement therapy, 371

TCu 380A, 17, 77

Testosterone,

    pharmacokinetics, 313

    transbuccal delivery system, 313

Testosterone buciclate, effect on reproductive and hormonal parameters (male monkey), 121

Testosterone buciclate + Antide (male monkey), 381

Testosterone enanthate, effect on lipoproteins, 115

Triglycerides level, effect of gossypol + chloroquine (male rat), 261

Uniplant subdermal implant, 111

Uterus, effect of anordiol (rat), 195

Vagina, effect of anordiol (rat), 195

Vascular events, OC users, 237

Voice function, effect of OCs, 343

Weight gain, users of contraceptives, 215